Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities remains negative

Q1 FY2026 other non-current liabilities was $7.98M, compared with $0 a year earlier.

Context

  • Other non-current liabilities amounted to 1.0% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
  • Other non-current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.98M+114.5% QoQ
Last fiscal yearDec 2025
-$55.01M-385.8% YoY
Year agoMar 2025
$0— since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-385.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
(55.01M) USD
Year-over-year change
-385.8%

Other Non-current Liabilities vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's Mar 2026 other non-current liabilities of $7.98M is the 2nd highest of the 3 companies compared; the peer median is $144.51M.
  • Other non-current liabilities amounts to 1.0% of total assets for PACB, versus a peer median of 2.2%.
PACB Competitors Peer median
Other Non-current Liabilities for PACB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ILMNIllumina, Inc.Jun 2026$289M +6.6%-17.8%4.3%
PACBPacific Biosciences of California, Inc.Mar 2026$7.98M ——1.0%
QSIQuantum-Si incorporatedMar 2026$25K -98.5%-67.6%0.0%
Peer median (excluding PACB) $144.51M-45.9%-42.7%2.2%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents460.73M325.09M179.91M55.37M63.71M
Short-term Investments583.68M447.23M451.51M334.56M215.8M
Net Receivables24.24M18.79M36.62M27.52M35.45M
Inventory24.6M50.38M56.68M58.76M49.29M
Other Current Assets500K300K17.34M19.47M10.79M
Total Current Assets1.1B852.07M742.05M495.68M375.03M
Property, Plant & Equipment (Net)79.12M81.34M69.03M46.6M65.84M
Goodwill409.97M409.97M462.26M317.76M317.76M
Intangible Assets410.98M410.25M456.98M389.57M15.12M
Long-term Investments00001.53M
Tax Assets00000
Other Non-current Assets5.76M13.45M15.7M10.84M8.79M
Total Non-current Assets905.84M915.01M1B764.77M409.05M
Total Assets2.01B1.77B1.75B1.26B784.08M
Account Payables11M12.03M15.06M16.59M20.77M
Short-term Debt1.61M1.84M490K0448K
Tax Payables00000
Deferred Revenue10.98M30.5M16.34M13.86M0
Other Current Liabilities4.15M175.5M7.84M3.22M32.75M
Total Current Liabilities71.71M263.34M95.03M66.3M54.42M
Long-term Debt896.07M896.68M892.24M647.49M702.42M
Deferred Tax Liabilities(25.05M)0000
Deferred Revenue (Non-current)25.05M1.79M5.53M5.9M19.87M
Other Non-current Liabilities198.24M1.3M20.3M19.25M(55.01M)
Total Non-current Liabilities1.14B940.85M949.68M687.55M724.32M
Total Liabilities1.22B1.2B1.04B753.85M778.73M
Common Stock221K227K268K294K302K
Retained Earnings(1.22B)(1.53B)(1.84B)(2.15B)(2.7B)
Accumulated OCI(1.09M)(4.77M)219K422K457K
Other Stockholders Equity00000
Minority Interest00000
Total Equity790.99M562.9M701.3M506.59M5.35M
Total Debt955.36M948.48M933.93M672.43M759.46M
Net Debt494.63M623.39M754.02M617.06M695.76M

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.